RESULT
Among the approved drug therapies for osteoporosis two classes of drugs are mostly used that are anti resorptive agents (e.g., bisphosphonates, estrogen, calcitonin and selective estrogen receptor modulators) and bone anabolic agent (recombinant human Para-thyroid hormone). Maximum patients in Pakistan were treated with bisphosphonate therapy due to economic status however few patients were prescribed the recombinant parathyroid hormone. There were no significant differences between baseline characteristics of the two drug classes.
A total of 200 patients were examined out of which 120 patients met inclusion criteria. These 120 patients involved 90 female and 30 male patients. Patients were diagnosed with osteoporosis of knee, back and lumber spine. Among 90 female patients11 of them withdrew therapy due to personal reasons as well as due to occurrence of adverse effects and two old ladies died not because of osteoporosis but because of other complications. Among female patients 75% females were post-menopausal, 27% were osteopenic and 63% were osteoporotic. Out of 30 male patients 4 patients gave up due to the adverse effects they experienced. Hence out of 26 male patients who continued therapy 33% male patients were osteopenic and 77% were osteoporotic with age above 50 years. 69% of the osteoporotic patients were treated with bisphosphonates and rest of 31% was recommended with rhPTH. The clinical design for current study including parameters is given in Table 1.